Health Care: Drugs

Geron Corp (GERN: NASDAQ)

$2.16 n/a | n/a%
09/29/14 - 03:59 PM ET
Company Profile
Price and Volume
Recent Price 2.16
52 Week High 7.36
52 Week Low 1.31
Avg. Daily Vol. (Mil) 2.34
Beta (3 year) 2.31
Share Related Items
Mkt Cap (Mil) 338.87
Shares Out (Mil) 156.88
Float (Mil) 136.31
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 29.80
Current Ratio 30.00
LT Debt/ Equity 0.00
Total Debt / Equity 0.00
Valuation Ratios
Price Earnings n.a.
Price/Sales 277.53
Price/Book 2.34
Price/Cash Flow -10.50
Per Share Data
Earnings -0.25
Sales 0.01
Book Value 0.92
Cash Flow -0.21
Business Summary
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.
General Information
149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
www.geron.com
Industry : Drugs
Sector: Health Care
Employees: 46
CEO: Dr. John A. Scarlett,M.D
Short Interest
Current Month (Mil) 27.51
Previous Month (Mil) 25.51
Short Interest Ratio (Days) 14.50
Management Effectiveness
Return on Equity n.a.
Return on Assets -23.20
Return on Investments -24.00
Profitability
Gross Margin n.a.
EBIT Margin n.a.
Profit Margin 0.00

Portfolios with GERN

Latest GERN Headlines from TheStreet

More Financial News for GERN

Press Releases for GERN

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter